Top Markets
#1 Pleasing Gold Pleasing Gold +1,497.26%
#2 PulseChain PulseChain +58.12%
#3 Merlin's Seal BTC Merlin's Seal BTC +33.63%
#4 Ontology Gas Ontology Gas +33.04%
#5 BOOK OF MEME BOOK OF MEME +29.03%
#6 ConstitutionDAO ConstitutionDAO +27.43%
#7 Collect on Fanable Collect on Fanable +24.55%
#8 Unit Pump Unit Pump +21.78%
#9 Pump.fun Pump.fun +21.78%
#10 Nockchain Nockchain +21.45%
Coin of the day
Pleasing Gold Pleasing Gold
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
InnoPharmax Inc. InnoPharmax Inc.

InnoPharmax Inc.

4172
Classement en actions #26286
InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan,... InnoPharmax Inc., established in 1994 and headquartered in Taipei, Taiwan, operates as a specialized pharmaceutical enterprise. The company's core activities revolve around the development and market introduction of therapeutic products, with a particular focus on oncology and various other specialized medical fields within the Taiwanese market. Their current commercial portfolio encompasses N11005, an oral insulin designed for administration with meals, alongside GemOral. They also provide an Imipenem and Cilastatin solution, utilized for treating a broad spectrum of bacterial infections affecting areas such as the lower respiratory tract, skin and soft tissue, internal abdominal organs, gynecological systems, and bone and joints. Furthermore, InnoPharmax offers contrast agents, specifically gadopentetate dimeglumine and gadodiamide; oncology medications like Innomustine and Immurin; and Inpheno tablets, which are indicated for rare diseases. The company also provides advanced technology platforms, including the MUCR system, OralPas, and OralPas Pro. Looking at its research and development pipeline, InnoPharmax has several promising candidates. D07001 is currently in Phase I clinical trials for tumor treatment. C08001 has progressed to Phase III, targeting hypertension, heart failure, and left ventricular dysfunction following a myocardial infarction. Additional compounds in pilot bioequivalence (BE) trials include D07002, a potential supplement for phenylketonuria; C07001 for the management of Parkinson's disease; and N11001, which is being investigated for urological applications. The company is also actively formulating new contrast agents, D0131502 and D0051301.
Prix de l'action
$0.35614911
Capitalisation boursière
$41.95M
Changement (1 jour)
0.45%
Changement (1 an)
-50.84%
Pays
TW
Échange InnoPharmax Inc. (4172)

Catégorie

Healthcare
Marge opérationnelle de InnoPharmax Inc. (4172)
Marge opérationnelle au 2026 TTM : 0.00%
Selon les derniers rapports financiers et le cours de l'action de InnoPharmax Inc., la marge opérationnelle actuelle (TTM) est de 0.00%. À la fin de 2026, elle était de 0.00%.
Historique de la marge opérationnelle pour InnoPharmax Inc. de 2026 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
Pas assez de données pour les dates fournies.
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.